연구동향 분석
박사

근치적 간절제술 후 간세포암종의 재발과 혈관신생관련 유전자의 다형성

임정우 2015년

논문상세정보
인용/피인용
' 근치적 간절제술 후 간세포암종의 재발과 혈관신생관련 유전자의 다형성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • angiogenesis-related gene
  • hepatocellular carcinoma
  • recurrence
  • single nucleotide polymorphism
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
410 0

0.0%

' 근치적 간절제술 후 간세포암종의 재발과 혈관신생관련 유전자의 다형성' 의 참고문헌

  • von Marschall Z, Cramer T, Hocker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001;48:87-96.
  • Zhang CH, Xu GL, Jia WD, et al. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009;124:2982-8.
  • Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
  • Wang J, Xu Y, Xu Y, et al. Urocortin's Inhibition of Tumor Growth and Angiogenesis in Hepatocellular Carcinoma via Corticotrophin-Releasing Factor Receptor 2. Cancer Investigation 2008;26:359-368.
  • Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Letters 2008;267:226-244.
  • Valfre di Bonzo L, Novo E, Cannito S, et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009;24:1323-41.
  • Ueshima K, Kudo M, Nagai T, et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology 2008;75 Suppl 1:106-13.
  • Uenishi T, Nishiguchi S, Tanaka S, et al. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008;98:358-62.
  • Tsuzuki T, Sugioka A, Ueda M, et al. Hepatic resection for hepatocellular carcinoma. Surgery 1990;107:511-20.
  • Tang SH, Hu W, Hu JJ, et al. Hepatitis B virus X protein promotes P3 transcript expression of the insulin-like growth factor 2 (IGF2) gene via inducing hypomethylation of P3 promoter in hepatocellular carcinoma. Liver Int 2014.
  • Takenaka K, Yamamoto K, Taketomi A, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995;22:20-4.
  • Su H, Zhao J, Xiong Y, et al. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res 2008;641:27-35.
  • Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
  • Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003;198:1391-1402.
  • Sandhu DS, Baichoo E, Roberts LR. Fibroblast growth factor signaling in liver carcinogenesis. Hepatology 2014;59:1166-73.
  • Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008;47:929-936.
  • Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
  • Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006;242:151-167.
  • Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151-67.
  • Oka Y, Waterland RA, Killian JK, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002;35:1153-1163.
  • Nagorney DM, van Heerden JA, Ilstrup DM, et al. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989;106:740-8; discussion 748-9.
  • Moon HE, Cheon H, Chun KH, et al. Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncol Rep 2006;16:929-935.
  • Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54.
  • Mann CD, Neal CP, Garcea G, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007;43:979-92.
  • Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
  • Lee SH, Chung YH, Kim JA, et al. Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver Int 2012;32:457-66.
  • Lee D, Chung YH, Kim JA, et al. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer 2013;119:2239-46.
  • Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
  • Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007;46:446-455.
  • Kin M, Sata M, Ueno T, et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997;27:677-87.
  • Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005;42:846-853.
  • Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
  • Hanafusa T, Yumoto Y, Nouso K, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Letters 2002;176:149-158.
  • Gu X, Qi P, Zhou F, et al. An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population. Hum Genet 2010.
  • Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322-30.
  • De Souza AT, Hankins GR, Washington MK, et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449.
  • Chen MF, Jeng LB, Lee WC, et al. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery 1998;123:554-9.
  • Chen MF, Hwang TL, Jeng LB, et al. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989;124:1025-8.
  • Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19:111-120.
  • Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma Clin Chem Lab Med. 2009;47:412-418.
  • Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
  • Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
  • Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-75.
  • 37 -